A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol

Trial Profile

A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Allopurinol (Primary) ; Lesinurad (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Extension
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 17 Jun 2017 Pooled safety results from three large pivotal studies and their extensions (CRYSTAL, CLEAR-1, CLEAR-2, CRYSTAL extension and CLEAR extension), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 13 Nov 2016 Integrated safety data for lesinurad based on patients from CLEAR 1, CLEAR 2, CRYSTAL, CLEAR extension and CRYSTAL extension trials were presented at the American College of Rheumatology 2016 Annual Meeting, according to an Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top